Eleanor T. Mcfadden
46 works · 21,350 citations · h-index 17
Top works
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
- Leukemia and Preleukemia after Adjuvant Treatment of Gastrointestinal Cancer with Semustine (Methyl-CCNU)
- Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
- 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
- Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
- Cooperative groups and community hospitals. Measurement of impact in the community hospitals
- Population-Based Colonoscopy Screening for Colorectal Cancer
- Nodular histiocytic lymphoma:Factors influencing prognosis and implications for aggressive chemotherapy
- A retrospective study of earliest indicators of recurrence in patients on eastern cooperative oncology group adjuvant chemotherapy trials for breast cancer. A preliminary report
- Rationale and design of the European Polyp Surveillance (EPoS) trials
- Management of Data in Clinical Trials
- Approaches to data management
- The impact of registration of clinical trials units: The UK experience
- Abstract PD5-01: HERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis
- OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)
- Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)
- Data Definition, Forms, and Database Design
- Intergroup participation—The challenge of multigroup trials